Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Clovis Oncology (CLVS) stocks in Canada

Learn how to easily invest in Clovis Oncology stocks.

Clovis Oncology (CLVS) is a leading biotechnology business based in the US. It opened the day at $5.41 after a previous close of $5.39. During the day the price has varied from a low of $5.235 to a high of $5.46. The latest price was $5.42 (25 minute delay). Clovis Oncology is listed on the NASDAQ and employs 429 staff. All prices are listed in US Dollars.

How to buy shares in Clovis Oncology

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CLVS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Clovis Oncology stock price (NASDAQ:CLVS)

Use our graph to track the performance of CLVS stocks over time.

Clovis Oncology shares at a glance

Information last updated 2021-07-09.
Previous close$5.39
Change $0.03
Change % 0.5566%
Volume 3,341,593
Information last updated 2022-01-23.
52-week range$1.97 - $11.10
50-day moving average $3.01
200-day moving average $4.58
Wall St. target price$6.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-2.78

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Clovis Oncology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Clovis Oncology price performance over time

Historical closes compared with the close of $5.42 from 2022-01-26

1 week (2022-01-21) 147.49%
1 month (2021-12-24) N/A
3 months (2021-10-28) 23.74%
6 months (2021-07-28) 6.48%
1 year (2021-01-28) -35.55%
2 years (2020-01-27) -36.76%
3 years (2019-01-25) 24.48
5 years (2017-01-27) 62.5

Is Clovis Oncology under- or over-valued?

Valuing Clovis Oncology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Clovis Oncology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Clovis Oncology's PEG ratio

Clovis Oncology's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.13. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Clovis Oncology's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Clovis Oncology financials

Revenue TTM $156.1 million
Gross profit TTM $128.4 million
Return on assets TTM -26.4%
Return on equity TTM 0%
Profit margin -191.62%
Book value $-0.56
Market capitalisation $284.7 million

TTM: trailing 12 months

Clovis Oncology share dividends

We're not expecting Clovis Oncology to pay a dividend over the next 12 months.

Clovis Oncology share price volatility

Over the last 12 months, Clovis Oncology's shares have ranged in value from as little as $1.9701 up to $11.1. A popular way to gauge a stock's volatility is its "beta".

CLVS.US volatility(beta: 1.58)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Clovis Oncology's is 1.5849. This would suggest that Clovis Oncology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Clovis Oncology overview

Clovis Oncology, Inc. , a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U. S. , the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein.

Stocks similar to Clovis Oncology

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site